RRML - Clinical, laboratory and molecular features in essential thrombocythemia

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- September 2023 -
Approaching Risk Management in... 11
Romanian Review of Laboratory ... 10
Understanding the key differen... 9
D-dimers and ferritin: Expandi... 8
Monitoring CAR T cells in peri... 8
Levels and diagnostic values o... 7
Validation of GOD / PAP method... 5
Correction of the article: Pla... 5
An experimental in-vitro study... 5
Ferritin and procalcitonin in ... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 19(2)/2011

Clinical, laboratory and molecular features in essential thrombocythemia

Laura G. Urian, Adrian P. Trifa, Ljubomir Petrov, Mariana Paţiu


Essential thrombocyhtemia is a BCR-ABL negative myeloproliferative disorder (MPD) distinct from polycytemia vera and idiopathic myelofibrosis and characterized by persistent thrombocytosis, excessive proliferation of megakariocytes in the bone marrow, normal erythrocytic mass and the absence of prominent bone marrow fibrosis. In the last few years new information on pathogenesis of myeloproliferative disorders became available: the discovery of an acquired recurrent molecular abnormality in the 14th exon of the JAK2V617F gene resulting in a substitution of valine for phenylalanine at position 617 in the JAK2 protein (V617). We analyzed the recently identified JAK2V617F mutational status, the relevance of mutated allele burden for clinical presentation, thrombosis and hemorrhagic complications.

Keywords: essential thrombocytemia,mutation JAK2 V617F,thrombosis and hemorrhagic complications

  PDF Download full text PDF
(226 KB)
How to cite
Urian LG, Trifa AP, Petrov L, Paţiu M. Clinical, laboratory and molecular features in essential thrombocythemia. Rev Romana Med Lab. 2011;19(2):129-38